** Shares of drug developer Evoke Pharma more than double to $12.56 premarket
** Co says Gimoti, the nasal spray version of drug metoclopramide, when given to patients on GLP-1 weight loss treatments showed better reduction in symptoms compared to the oral version of metoclopramide
** EVOK says Gimoti can be used to treat patients on GLP-1 drugs with gastroparesis, a medical condition that prevents the stomach from emptying food and liquids properly
** Up to last close, stock down 58% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.